Tysabri

Switching to one of the anti-CD20 targeting therapies Ocrevus (ocrelizumab) or rituximab may be an effective strategy for discontinuing Tysabri (natalizumab) treatment in multiple sclerosis (MS) patients at risk for progressive multifocal leukoencephalopathy (PML), according to a systematic review. The study, “Switching from natalizumab to an…

People with multiple sclerosis (MS) who are being treated with Tysabri (natalizumab) tend to prefer receiving the medication as a subcutaneous (under-the-skin) injection rather than an intravenous (into-the-vein) infusion, according to new data from an observational study. “Based on current data, there is a trend toward patients’ preference…

People who start treatment with Tysabri (natalizumab) soon after being diagnosed with multiple sclerosis (MS) are at a lower risk of relapse in the long term compared with patients who start on less effective disease-modifying therapies (DMT), a study has found. Patients on Tysabri, an antibody-based therapy,…

The European Commission has approved Tyruko (natalizumab), the first biosimilar of Tysabri, for the treatment of adults with highly active relapsing-remitting multiple sclerosis (RRMS). The approval makes Tyruko available in the European Union for the same indication as its reference medicine. It also marks the first approval…

Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple sclerosis (RRMS), according to a new study. The therapy also eased or stabilized disability levels in most patients after five years of treatment, and significantly reduced the annual rate of…

The late August approval of Tyruko (natalizumab-sztn) by the U.S. Food and Drug Administration (FDA) is big news in the multiple sclerosis (MS) world. Tyruko is a biosimilar for Tysabri (natalizumab), and it’s the first biosimilar to gain FDA approval as an MS disease-modifying therapy…

The U.S. Food and Drug Administration (FDA) has approved Tyruko (natalizumab-sztn) as the first biosimilar of Tysabri to treat adults with relapsing forms of multiple sclerosis (MS). The decision also marks the first approval of any biosimilar for MS in the country, according to the regulatory agency.

Levels of GFAP protein in the blood — a marker of damage to support cells in the brain — were associated with the enlargement of brain lesions and of fluid-filled brain cavities called ventricles in people with relapsing-remitting MS (RRMS) undergoing Tysabri (natalizumab) treatment, a study showed. While…

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that PB006, a biosimilar version of Tysabri (natalizumab), be approved to treat adults with highly active relapsing-remitting multiple sclerosis (RRMS). The recommendation comes about a year after the regulatory agency…

Tysabri (natalizumab) is better than five other disease-modifying therapies (DMTs) at reducing relapses and preventing disability worsening in relapsing-remitting multiple sclerosis (RRMS), according to the findings of a novel simulated clinical trial that directly compared the six treatments. The analysis used mathematical modeling to emulate a clinical trial…

Switching from Tysabri (natalizumab) to Ocrevus (ocrelizumab) does not appear to increase disease activity in people with relapsing forms of multiple sclerosis (MS) and stable disease, with most patients continuing to show no relapses or brain imaging findings one year after the transition, a clinical study shows.

Ocrevus (ocrelizumab) — given by infusion — may work better than certain oral treatments to prevent relapses and disability worsening in people with relapsing-remitting multiple sclerosis (RRMS) who transition from Tysabri (natalizumab), a new study found. Individuals who switched to Ocrevus also were more likely to stay…

Tysabri (natalizumab) is generally safe and effectively lowers disease activity in people with multiple sclerosis (MS), according to a real-world study of patients over a 13-year period in Denmark. “Most patients treated with [Tysabri] are clinically stable with few adverse events,” researchers wrote. In more recent years, doctors…

PB006, a biosimilar to Biogen’s approved treatment Tysabri (natalizumab), showed similar safety and efficacy as the original medication in people with relapsing-remitting MS (RRMS), according to data from a Phase 3 clinical trial. “The Antelope trial reported equivalence between [PB006 and Tysabri] treatment across efficacy, safety, and secondary…

Autologous hematopoietic stem cell transplant (aHSCT) is superior to Gilenya (fingolimod) and Tysabri (natalizumab) at preventing relapses and reducing disability in people with highly active relapsing-remitting multiple sclerosis (RRMS). In turn, aHSCT appears to be as effective as Ocrevus (ocrelizumab) in RRMS patients and also was…

Long-term treatment with Tysabri (natalizumab) significantly improves cognitive function and increases the chance of disability reduction in people with early relapsing-remitting multiple sclerosis (RRMS), according to data from the four-year observational STRIVE trial. Patients on Tysabri also reported improved quality of life and less impact of MS on…

People with relapsing multiple sclerosis (MS) treated with Tysabri (natalizumab) or Gilenya (fingolimod) are less likely to have disease activity than those on low-efficacy MS medications, according to a small study conducted in Japan. Results also showed that patients receiving the high-efficacy therapies had less brain shrinkage,…

Anti-CD20 Therapies Help Mount T-cell Response to COVID-19 Vaccines Since the start of the COVID-19 pandemic, there have been concerns that anti-CD20 therapies, such as Ocrevus (ocrelizumab), may interfere with the ability of a person with MS to fight a COVID-19 infection. But this report says that even if…

Tysabri (natalizumab) outperforms other disease-modifying therapies (DMTs) in its ability to lessen a range of patient-reported symptoms in people with multiple sclerosis (MS), according to data from a large real-world study. These symptoms include balance difficulties, sensory problems, feelings of anxiety, bladder problems, vision problems, and…

Stem Cell Transplant Found to Reduce MS Relapses, Ease Disability This is excellent news for those of us who would like to see stem cell transplant for MS become more available and affordable. These researchers analyzed 50 studies covering a total of 4,831 people with MS, ages 26 to…

Switching from a standard monthly course of Tysabri (natalizumab) to an extended-interval dosing administered every six weeks does not seem to increase neuronal damage in people with multiple sclerosis (MS), a study found. While individual blood levels of neurofilament light chain (NfL), a biomarker of nerve damage, did…

No Link Between MS Severity, Vitamin D-related Mutations: Study Several studies over the years have indicated that there could be a link between a person’s vitamin D level and the risk of multiple sclerosis (MS). This study is slightly different. Researchers looked at whether genetic variations related to vitamin…

The U.S. Food and Drug Administration (FDA) has agreed to review an application requesting that Polpharma Biologics‘ natalizumab, a biosimilar of Tysabri, be approved to treat relapsing forms of multiple sclerosis (MS). Its intended U.S. use is for the same indications as the approved name-brand medicine, covering clinically isolated…

The European Medicines Agency (EMA) has agreed to review a request to approve Polpharma Biologics‘ biosimilar natalizumab for the treatment of multiple sclerosis (MS). This marks the first time the regulatory agency accepted a marketing authorization application for a biosimilar of Tysabri, an approved MS treatment. “The acceptance…

Kesimpta (ofatumumab) may be more effective at reducing relapse rates than other disease-modifying therapies (DMTs) in Japanese adults with relapsing forms of multiple sclerosis (MS), according to a review of clinical trial data. Although the differences were not statistically significant, the study provided comparative evidence that may help…

Gilenya (fingolimod) and Tysabri (natalizumab) were more effective at lowering relapse rates in children with multiple sclerosis (MS) than interferon-beta, according to a recent meta-analysis. Findings like these can be leveraged for better clinical trial design, the researchers wrote. If used to determine “historical” relapse rates that…

Multiple sclerosis (MS) patients with fatigue have significantly lower levels of amyloid precursor protein (APP) — a molecule involved in nerve cell function — in the cerebrospinal fluid (CSF) relative both to those without this common symptom and healthy people, a study shows. The CSF is the liquid…

Cannabis ‘Highly Effective’ Against MS Symptoms, Some Users Report I would’ve expected many users to report that cannabis has been highly effective at treating MS symptoms, not just some. But comments about this study on the MS News Today Facebook page indicate that people have mixed results. Even…

Tysabri (natalizumab) given every six weeks was found to be similarly effective as the standard four-week dosing schedule at stopping nervous system damage in people with relapsing-remitting multiple sclerosis (RRMS). That’s according to the full results of the Phase 3b NOVA clinical trial, which compared Tysabri dosing schedules…

Treatment with Gilenya (fingolimod) for up to four years was found safe and lowered relapse rates among people with multiple sclerosis (MS) in the Czech Republic, according to a real-world study called GOLEMS. Older age, lower disability level, and fewer relapses prior to the treatment’s start were all…